PPBT Purple Biotech Ltd: רווח למניה לשנה מתגלגלת

The EPS growth rate over the last 12 months YoY demonstrates profit dynamics, where the latest parameter stands at -151.70. Purple Biotech (PPBT) develops agents to combat tumor resistance in complex cases. Antibody production is outsourced to external centers in Europe and the US. The asset value is not tied to current prices but is based on the results of clinical trials.

This indicator serves as a fundamental tool for assessing the efficiency of earnings per share generation. It measures the percentage change in net income over a rolling year, capturing the dynamics of the business's real profitability. By analyzing the historical delta of EPS YoY TTM, an investor determines the company's ability to scale profits. For Purple Biotech (PPBT), this growth confirms the commercial success of developing combined onco-immunological therapies. The positive trend here signals growing physician confidence in new methods of fighting cancer.